News & Events

HighTide’s drug candidate, HTD1801, Awarded 2017 National Science and Technology Major Project

March 01, 2018

HTD1801, one of HighTide’s lead candidates, awarded a grant in China as the ‘National Science and Technology Major Project’ for ‘New Drug Research and Development’ in November 2017. HTD1801 is under development for the treatment of primary sclerosing cholangitis (PSC), non-alcoholic steatohepatitis (NASH) and hypercholesterolemia.


This award qualifies HTD1801 a priority regulatory review status for the China market. Total grant is $1.25 million.

Share on WeChat circle of friends ×
Open WeChat
Use Scan to share web pages with your friends.

HighTide,君圣泰,君圣泰医药,非酒精性脂肪性肝炎,nash,2型糖尿病,t2dm

We will contact you as soon as possible

HighTide,君圣泰,君圣泰医药,非酒精性脂肪性肝炎,nash,2型糖尿病,t2dm HighTide,君圣泰,君圣泰医药,非酒精性脂肪性肝炎,nash,2型糖尿病,t2dm HighTide,君圣泰,君圣泰医药,非酒精性脂肪性肝炎,nash,2型糖尿病,t2dm HighTide,君圣泰,君圣泰医药,非酒精性脂肪性肝炎,nash,2型糖尿病,t2dm

© 2024 HighTide Therapeutics, Inc.

Legal StatementPrivacy PolicyCookie Policy

收起
En

Follow Us

© 2024 HighTide Therapeutics, Inc.